Clinical Study on Acetyl-L-Carnitine
Chemotherapy-induced peripheral neuropathy (CIPN) is a common clinical dose-limiting adverse drug reaction, and the primary manifestations are different degree of neuromotor, sensorineural and autonomic nervous dysfunction.
Peripheral Sensory Neuropathy
DRUG: Acetylcarnitine|DRUG: Placebo
Changes in peripheral sensory neuropathy grades, Changes in peripheral sensory neuropathy grades after eight weeks treatment, Base and eighth week
Changes in Neuroelectrophysiological test, Changes in Neuroelectrophysiological test after eight weeks ALC or placebo treatment, Base and eighth week|Changes in Cancer-related fatigue level, Changes in Cancer-related fatigue level after eigth weeks treatment, Base and eighth week|Changes in Physical Condition Score, Changes in Physical Condition Score after eight weeks treatment, Base and eighth week
This multicenter, randomized, double-blind, placebo-controlled and parallel clinical trial is to observe the efficacy and safety of the Acetyl-L-Carnitine Hydrochloride enteric-coated tablets in treatment of peripheral sensory neuropathy that anti-cancer chemotherapeutics induce.